Из-за периодической блокировки нашего сайта РКН сервисами, просим воспользоваться резервным адресом:
Загрузить через dTub.ru Загрузить через ClipSaver.ruУ нас вы можете посмотреть бесплатно Blood phosphorylated tau as biomarkers for Alzheimer’s disease│Dr. Thomas K. Karikari или скачать в максимальном доступном качестве, которое было загружено на ютуб. Для скачивания выберите вариант из формы ниже:
Роботам не доступно скачивание файлов. Если вы считаете что это ошибочное сообщение - попробуйте зайти на сайт через браузер google chrome или mozilla firefox. Если сообщение не исчезает - напишите о проблеме в обратную связь. Спасибо.
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса savevideohd.ru
Summary: Alzheimer's disease (AD) is the most common cause of dementia, and its health and socioeconomic burdens are of major concern. Presently, a definite diagnosis of AD is established by examining brain tissue after death. These examinations focus on two major pathological hallmarks of AD in the brain: (i) amyloid plaques consisting of aggregated amyloid beta (Aβ) peptides and (ii) neurofibrillary tangles made of abnormally phosphorylated tau protein. In living individuals, AD diagnosis relies on two main approaches: (i) brain imaging of tau tangles and Aβ plaques using a technique called positron emission tomography (PET) and (ii) measuring biochemical changes in tau (including phosphorylated tau at threonine-181 [p-tau181]) and the Aβ42 peptide metabolized into CSF. Unlike Aβ42, CSF p-tau181 is highly specific for AD but its usability is restricted by the need of a lumbar puncture. Moreover, PET imaging is expensive and only available in specialised medical centres. Due to these shortcomings, a simple blood test that can detect disease-related changes in the brain is a high priority for AD research, clinical care and therapy testing. In this webinar, I will discuss the discovery of p-tau biomarkers in blood and the biochemistry of how these markers differ from those found in CSF. Furthermore, I will critically review the performance of blood p-tau biomarkers across the AD pathological process and how they associate with and predict Aβ and tau pathophysiological and neuropathological changes. Furthermore, I will evaluate the potential advantages, challenges and context of use of blood p-tau in clinical practice, therapeutic trials and population screening. Speaker Bio: Thomas is an Assistant professor of neurochemistry at the University of Gothenburg in Sweden. He holds a research fellowship from the BrightFocus Foundation and is the principal investigator of grants from the Swedish Alzheimer Foundation, the Swedish Brain Foundation, the Swedish Dementia Foundation and several other bodies. His main research interest is to understand the processing of tau protein in the Alzheimer brain and apply this knowledge to develop new CSF and blood biomarkers for clinical use. To this end, he has approximately 40 PubMed-indexed publications and a pending patent. Thomas has received two major awards for his discovery and development of blood p-tau biomarkers for clinical use. First, he was co-awarded the best scientific discovery award in the Alzheimer field in Sweden over 2019-2020. Secondly, he won the Astrup Prize for contemporary work in clinical chemistry, awarded by The Nordic Federation for Clinical Chemistry. Thomas was awarded his PhD in 2018 from Warwick university in Coventry, UK, funded by the Biotechnology and Biological Sciences Research Council (BBSRC). He published five first-author papers from his PhD project on which he doubled as the corresponding author. At the end of his PhD, Thomas was a visiting scholar at Harvard Medical School with fellowships from the Royal Society of Chemistry and the BBSRC. Previously, he had completed his bachelor’s education in biochemistry in his native Ghana, with first-class honours and was awarded a Dean’s Award for Academic Excellence. This was followed by a master’s degree in pharmaceutical biotechnology in Leicester funded by a Commonwealth scholarship. Moderator: Mahmoud Maina, PhD, University of Sussex, UK. https://en.wikipedia.org/wiki/Mahmoud... Coordinator: Mosab Ali Awadelkareem, Al-Neelain University, Sudan. Society of Neuroscientists of Africa – SONA: https://sonafrica.org/ / sonaorg / society-of-neuroscientists-of-africa-sona-... / @societyofneuroscientistsof385 TReND in Africa: https://trendinafrica.org/ https://www.flickr.com/photos/trendin... https://twitter.com/trendinafrica?lan... / trendinafrica Worldwide Neuro: https://www.worldwideneuro.com/ / worldwideneuro